Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660261 | 0.81 | MAOB (0.30) | MAOBCA1CA2 | |
| SCHEMBL660484 | 0.79 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9028205 | 0.78 | MAOB (0.38) | MAOBAPPALDH1A1 | |
| SCHEMBL14283810 | 0.74 | KDM4E (0.34) | MAOBAPPALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL2047102 | 0.74 | PGK1 (0.39) | PGK1PGK2SLC11A2SIRT1FASN | |
| SCHEMBL24067448 | 0.72 | PGK1 (0.38) | PGK1PGK2SLC11A2SIRT1ALDH1A1 | |
| SCHEMBL1721102 | 0.72 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL660212 | 0.72 | GAA (0.40) | PGK1PGK2MAOBSLC11A2APP | |
| SCHEMBL9028451 | 0.72 | SELL (0.39) | MAOBAPPALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL8627521 | 0.72 | ALOX5 (0.40) | APPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-7553837-B2 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553837-B2 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1650206-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS, AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-5770772-A | 4-FORMYLAMINO-2,3,5-TRIMETHYL-1-(2-METHYL-2-PROPENYLOXY) -BENZENE; ARTERIOSCLEROSIS, BRAIN AND CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5594154-A | 5-AMINO-2-BROMOMETHYL-2,4,6,7-TETRAMETHYL-2,3-DIHYDROBENZO(B) FURANS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| US-5478844-A | Method of using aminocoumaran derivatives for treating cerebrovascular diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0483772-B1 | Aminocoumaran derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-09-13 | — | — | EP | disclosed |
| US-5376681-A | Aminocoumaran derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0483772-A1 | Aminocoumaran derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | PGK1 4731/4885PGK2 4138/4885MAOB 585/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | PGK1 4731/4885PGK2 4138/4885MAOB 585/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | PGK1 4731/4885PGK2 4138/4885MAOB 585/4885 |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | CBR1, CBR3, NOX3 | PGK1 3400/4885PGK2 3304/4885MAOB 169/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | PGK1 3946/4885PGK2 2972/4885MAOB 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.